Voyager Therapeutics CEO Alfred Sandrock sells $49,616 in stock

Published 24/02/2025, 22:24
Voyager Therapeutics CEO Alfred Sandrock sells $49,616 in stock

Alfred Sandrock, the President and CEO of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech company with a market capitalization of $225 million and strong financial health according to InvestingPro, recently sold shares of the company, according to a Form 4 filing with the Securities and Exchange Commission. On February 20, Sandrock sold 11,702 shares of common stock at an average price of $4.24 per share, totaling $49,616. The sale occurred with the stock trading near its 52-week low and showing oversold conditions based on technical indicators. Following this transaction, Sandrock holds 296,816 shares directly. InvestingPro analysis shows 8 additional key insights about VYGR’s current market position.

In addition to the sale, Sandrock acquired 145,000 restricted stock units on February 21, 2025, at no cost, as part of Voyager Therapeutics’ 2015 Stock Option and Incentive Plan. These units vest over a three-year period. Sandrock also received stock options for 290,000 shares, which will vest over four years, further strengthening his position in the company, which maintains a healthy balance sheet with a current ratio of 8.45 and trades at a P/E ratio of 8.87.

In other recent news, Voyager Therapeutics announced a delay in its investigational new drug (IND) application for its ALS gene therapy candidate, VY9323, initially expected in mid-2025. The company is reassessing its approach due to off-target effects in non-human primate studies and will explore alternative payloads. Despite this setback, Voyager’s other gene therapy programs, including those for GBA1 Parkinson’s disease and Friedreich’s ataxia, remain on schedule, with IND filings anticipated in 2025. Analysts from H.C. Wainwright and Citi have maintained a positive outlook on Voyager Therapeutics, with H.C. Wainwright setting a $30 price target and Citi assigning a $12 target, both highlighting the company’s strong gene therapy pipeline. Voyager’s financial outlook appears stable, with cash reserves projected to last until mid-2027. The company’s proprietary TRACER platform continues to be a focal point, promising advancements in CNS gene therapy. Collaborative efforts with Neurocrine (NASDAQ:NBIX) Biosciences are ongoing, with plans to file additional IND applications. Voyager’s leadership remains optimistic about addressing unmet medical needs in neurological disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.